June 22, 2024
Global In Vitro Lung Model

The Global In Vitro Lung Model Market is Trending Due to Growing Demand for Alternatives to Animal Testing

In vitro lung models can be used to replicate important functions and structures of the lung through the use of lung cell cultures, microfluidic chips, and tissue-engineered constructs. These models provide useful insights into the biology of the lung and preclinical evaluation of compounds while adhering to the principles of the 3Rs in research.

The Global In Vitro Lung Model Market is estimated to be valued at US$ 245.0 Mn in 2024 and is expected to exhibit a CAGR of 14% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the global in vitro lung model market are Epithelix, MATTEK, Lonza, Emulate, AlveoliX AG, Nortis, CN Bio Innovations Ltd, MIMETAS, InSphero, ATTC Global, Tissuse GmbH and Cn Bio Innovations Limited. These companies offer a variety of 2D and 3D in vitro lung models for applications such as drug screening, toxicology evaluation, and disease modeling.

The demand for in vitro lung models is growing rapidly due to increasing focus on developing alternatives to animal testing in research. Various industries such as pharmaceutical, biotechnology, and cosmetics are adopting 3D organ chip technology and tissue-engineered models to evaluate drug toxicity and efficacy in a human-relevant manner.

The market is also witnessing increased global expansion as companies look to establish manufacturing and distribution facilities across North America, Europe, Asia Pacific and other regions to cater to the local demand. New product launches and technological advancements in the field of organ-on-chip devices and microphysiological systems will further support the growth of the in vitro lung model market during the forecast period.

Market Key Trends

A major trend gaining traction in the Global In Vitro Lung Model Market Size is the development of multi-organ microfluidic chips and organ-on-chip devices. Researchers are integrating lung and other organ models like gut, liver, heart on a single microchip to mimic the complex human physiology. Such multi-organ systems allow evaluation of systemic toxicity and organ interactions in a preclinical setting. Epithelix has launched a lung-liver model whereas companies like Emulate and CN Bio are releasing integrated systems combining up to four organ chips. Growing research in the domain of multi-organ interactions using microfluidic technology will continue shaping the future of the in vitro lung model industry.

Porter’s Analysis

Threat of new entrants: Due to high capital cost and requirement of skilled labor, threat is low.

Bargaining power of buyers: Moderate bargaining power as these models are used in research labs.

Bargaining power of suppliers: Moderate as well established suppliers are there.

Threat of new substitutes: Low as no close substitutes are available for these models at present.

Competitive rivalry: High as key players compete on technological advancements, collaboration and mergers.

Geographical Regions

North America dominates the global market in terms value due to increasing funding for lung disease research. Majority of key players are also based in this region.

Asia Pacific is expected to be the fastest growing regional market during forecast period. Increasing R&D investments by government as well as private players in countries like China and India will drive the market in this region.

Europe accounts for a significant share in the global market value due to presence of major research centers involved in research activities for lung disease treatment. Major European countries contributing to the regional market are Germany, UK and France.

The market in Latin America and Middle East & Africa is expected to witness growth at a steady pace. This is attributed to increasing awareness about advanced lung models and their applications in research.

*Note:
1.Source: Coherent Market Insights, Public sources, Desk research
2.We have leveraged AI tools to mine information and compile it